Citations

Clear

4610 citation(s) found for "Lu, Brian".

A Comprehensive Approach to Sample Preparation for Electron Microscopy and the Assessment of Mitochondrial Morphology in Tissue and Cultured Cells
Hinton, Antentor , Christensen, Trace , Mungai, Margaret , Shao, Jianqiang, Trushin, Sergey , Alghanem, Ahmad F. , Jaspersen, Adam, Geroux, Rachel E., Neikirk, Kit , Biete, Michelle , Shao, Bryanna, Vue, Zer , Vang, Larry , Beasley, Heather K. , Stephens, Dominique, Ponce, Jessica, Bleck, Christopher K. E. , Hicsasmaz, Innes, Murray, Sandra , Edmonds, Ranthony A. C. , Dajles, Andres , Koo, Young Do , Bacevac, Serif, Salisbury, Jeffrey L., Pereira, Renata O. , Trushina, Eugenia , Pereira, Renata O , Hinton, Antentor , Beasley, Heather K , Murray, Sandra A , Trushina, Eugenia , Katti, Prasanna , Zhang, Liang , Garza-López, Edgar , Marshall, Andrea G. , Stephens, Dominique C., Damo, Steven M. , Glancy, Brian , Abel, E. Dale

Mayo Clinic

Advanced Biology | May 4, 2023 | Volume: 7 | Issue: 10 | Pages: No page available

10.1002/adbi.202200202 | PMID 37140138 Get It

Abstract Mitochondria respond to metabolic demands of the cell and to incremental damage, in part, through dynamic structural changes that include fission (fragmentation), fusion (merging of distinct mitochondria), autophagic degradation (mitophagy), and biogenic interactions with the endoplasmic reticulum (ER). High resolution study of mitochondrial structural and functional relationships requires rapid preservation of specimens to reduce technical artifacts coupled with quantitative assessment of mitochondrial architecture. A practical approach for assessing mitochondrial fine structure using two dimensional and three dimensional high‐resolution electron microscopy is presented, and a systematic approach to measure mitochondrial architecture, including volume, length, hyperbranching, cristae morphology, and the number and extent of interaction with the ER is described. These methods are used to assess mitochondrial architecture in cells and tissue with high energy demand, including skeletal muscle cells, mouse brain tissue, and Drosophila muscles. The accuracy of assessment is validated in cells and tissue with deletion of genes involved in mitochondrial dynamics.
Association of Specific “Critical” Demyelinating Lesions and Motor Impairment in Progressive Multiple Sclerosis: A Prospective Study (S46.008)
Ahmad, Rowaid, Jackson-Tarlton, Caitlin S. , Duffy, Dustin, Toledano, Michel , Lucchinetti, Claudia F. , Weinshenker, Brian G. , Kantarci, Orhun H. , Weinshenker, Brian G , Ahmad, Rowaid, Flanagan, Eoin P. , Messina, Steven A. , Tobin, W. Oliver , Pittock, Sean J. , Keegan, B. Mark

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202391 Get It

Correlates of Fluctuations in Moderate-Advanced Dementia with Lewy Bodies (P13-6.007)
Tholanikunnel, Tracy , LaBarre, Brian , Sovich, Kaitlin , Paulson, Henry L. , Maixner, Susan M. , Manning, Carol A. , Fields, Julie A. , Lunde, Angela , Boeve, Bradley, Forsberg, Leah K. , Armstrong, Melissa J. , Paulson, Henry L , LaBarre, Brian , Armstrong, Melissa J , Li, Zhigang , Galvin, James E. , Taylor, Angela E.

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202132 Get It

Patient Preferences for Attributes of Advanced Migraine Prevention Medications: Findings from a Discrete Choice Experiment (P7-12.004)
Kymes, Steven, Talon, Brian , Cady, Roger, Asher, Divya , Karnik-Henry, Meghana, Mulvihill, Emily , Bates, Dawn, Beusterien, Kathleen , Schwedt, Todd J. , Martin, Ashley , Lee, Xin Ying , Karnik‐Henry, Meghana

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000201891 Get It

The genetic determinants of recurrent somatic mutations in 43,693 blood genomes
Weinstock, Joshua S. , Laurie, Cecelia , Broome, Jai , Taylor, Kent D. , Guo, Xiuqing , Shuldiner, Alan R. , O’Connell, Jeffrey R. , Lewis, Joshua P. , Boerwinkle, Eric , Barnes, Kathleen C. , Chami, Nathalie , Loos, Ruth J. F. , Fornage, Myriam , Redline, Susan , Cade, Brian E. , Chen, Zhanghua , Gauderman, W. James , Schleimer, Robert P. , Bis, Joshua C. , Brody, Jennifer A. , Silverman, Edwin K. , Qiao, Dandi , Lasky‐Su, Jessica , DeMeo, Dawn L. , Palmer, Nicholette D. , Bowden, Donald W. , Johnson, Andrew D. , Yanek, Lisa R. , Becker, Lewis C. , Kardia, Sharon L.R., Kaplan, Robert C. , Heckbert, Susan R. , Smith, Nicholas L. , Arnett, Donna K. , Irvin, Marguerite R. , Tiwari, Hemant K., Raffield, Laura M. , Gao, Yan , Rotter, Jerome I. , Wheeler, Marsha M. , Duggirala, Ravindranath , Xiao, Shujie, Williams, L. Keoki , Meyers, Deborah A. , Ortega, Victor E. , McGarvey, Stephen T. , Chen, Yii‐Der Ida , Lee, Wen‐Jane , Shoemaker, M. Benjamin , Roden, Dan M. , Blackwell, Thomas W. , Smith, Albert V. , Kang, Hyun Min , Mathias, Rasika A. , Natarajan, Pradeep , Jaiswal, Siddhartha , Reiner, Alex P. , Bick, Alexander G. , Kaplan, Robert C. , Broome, Jai , Kenny, Eimear E , Loos, Ruth J F , Fornage, Myriam , Redline, Susan , Cade, Brian E , Gauderman, W James , Grammer, Leslie , Schleimer, Robert P , Bis, Joshua C , Brody, Jennifer A , Silverman, Edwin K , Yun, Jeong H , Qiao, Dandi , Weiss, Scott T , Palmer, Nicholette D , Freedman, Barry I , Cho, Michael H , Vasan, Ramachandran S , Johnson, Andrew D , Yanek, Lisa R , Becker, Lewis C , He, Jiang , Heckbert, Susan R , Wiggins, Kerri L , Arnett, Donna K , Correa, Adolfo , Raffield, Laura M , Gao, Yan , Rotter, Jerome I , Rich, Stephen S , Manichaikul, Ani W , Konkle, Barbara A , Johnsen, Jill M , Custer, Brian S , Duggirala, Ravindranath , Curran, Joanne E , Li, Xingnan , McGarvey, Stephen T , Gu, C Charles , Lee, Wen-Jane , Darbar, Dawood , Roden, Dan M. , Kooperberg, Charles , Desai, Pinkal M , Smith, Albert V , Kang, Hyun M , Mathias, Rasika A , Natarajan, Pradeep , Jaiswal, Siddhartha , Bick, Alexander G , Weinstock, Joshua S , Shuldiner, Alan R , Taylor, Kent D , Guo, Xiuqing , Lasky-Su, Jessica , Gilliland, Frank D. , Kumar, Rajesh , Psaty, Bruce M. , Yun, Jeong H. , Weiss, Scott T. , Freedman, Barry I. , Cho, Michael H. , Vasan, Ramachandran S. , He, Jiang , Wiggins, Kerri L. , Andrade, Mariza de , Rich, Stephen S. , Manichaikul, Ani , Konkle, Barbara A. , Custer, Brian , Curran, Joanne E. , Blangero, John , Gui, Hongsheng , Li, Xingnan , Darbar, Dawood , Albert, Christine M. , Kooperberg, Charles , Desai, Pinkal , Abecasis, Gonçalo R.

Mayo Clinic

Science Advances | April 26, 2023 | Volume: 9 | Issue: 17 | Pages: No page available

10.1126/sciadv.abm4945 | PMID 37126548 Get It

Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased with age, with an average 50-year-old having 27 RNMSMs. Inherited germline variation associated with RNMSM acquisition. These variants were found in genes involved in adaptive immune function, proinflammatory cytokine production, and lymphoid lineage commitment. In addition, the presence of eight specific RNMSMs associated with blood cell traits at effect sizes comparable to Mendelian genetic mutations. Overall, we found that somatic mutations in blood are an unexpectedly common phenomenon with ancestry-specific determinants and human health consequences.
Microfluidic ‘Brain-on Chip’ Systems to Supplement Neurological Practice: Development, Applications and Considerations
Jarrah, Ryan , Nathani, Karim Rizwan , Bhandarkar, Shaan , Ezeudu, Chibuze S., Nguyen, Ryan T. , Amare, Abrham, Aljameey, Usama A., Jarrah, Sabrina I., Bhandarkar, Archis R. , Fiani, Brian , Nathani, Karim Rizwan , Nguyen, Ryan T

Mayo Clinic

Regenerative Medicine | April 26, 2023 | Volume: 18 | Issue: 5 | Pages: 413-423

10.2217/rme-2022-0212 | PMID 37125510 Get It

Multiorganizational consensus to define guiding principles for perioperative pain management in patients with chronic pain, preoperative opioid tolerance, or substance use disorder
Dickerson, David , Mariano, Edward R. , Szokol, Joseph W., Harned, Michael , Clark, Randall M, Mueller, Jeffrey T. , Shilling, Ashley , Udoji, Mercy A. , Mukkamala, S Bobby, Doan, Lisa , Wyatt, Karla , Elkassabany, Nabil , Beck, Stacy , Wiechmann, Lisa, Chiao, Franklin, Halle, Steven G, Krishnan, Deepak G. , Cramer, John D. , Esa, Wael Ali Sakr, Muse, Iyabo O. , Baratta, Jaime L., Rosenquist, Richard W. , Gulur, Padma, Shah, Shalini , Kohan, Lynn , Robles, Jennifer, Yang, Stephen C. , Hadeed, Josef G., Schwartz, Gary , Sprintz, Michael, Urish, Kenneth L. , Walton, Ashley , Keith, Lauren, Buvanendran, Asokumar , Dickerson, David M , Muse, Iyabo O , Rosenquist, Richard , Schwenk, Eric S , Schwartz, Gary , Mariano, Edward R , Clark, Randall M., Schwalb, Jason M. , Eloy, Jean Daniel , Schwenk, Eric S. , Allen, Brian F.S. , Englesbe, Michael J. , Walton, Ashley, Keith, Lauren

Mayo Clinic

Regional Anesthesia & Pain Medicine | April 25, 2023 | Volume: 49 | Issue: 10 | Pages: 716-724

10.1136/rapm-2023-104435 | PMID 37185214 Get It

Significant knowledge gaps exist in the perioperative pain management of patients with a history of chronic pain, substance use disorder, and/or opioid tolerance as highlighted in the US Health and Human Services Pain Management Best Practices Inter-Agency Task Force 2019 report. The report emphasized the challenges of caring for these populations and the need for multidisciplinary care and a comprehensive approach. Such care requires stakeholder alignment across multiple specialties and care settings. With the intention of codifying this alignment into a reliable and efficient processes, a consortium of 15 professional healthcare societies was convened in a year-long modified Delphi consensus process and summit. This process produced seven guiding principles for the perioperative care of patients with chronic pain, substance use disorder, and/or preoperative opioid tolerance. These principles provide a framework and direction for future improvement in the optimization and care of ‘complex’ patients as they undergo surgical procedures.
Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes
Ambrose, Nalini, Anderson, Brian, Barrera-Oro, Julio, Campion, Francis X. , Danan, Risa, D’Arinzo, Lauren , Drews, Ashley, Erlandson, Karl J. , Fitzgerald, Kristin , García, Melissa, Gong, Carlene, Hanna, George J. , Lopansri, Bert K. , Musser, James M. , Piantadosi, Steven , Pritt, Bobbi S. , Roberts, Seth, Sandmeyer, Suzanne , Stein, David , Webb, Brandon , Yttri, Jennifer, O'horo, John, Pritt, Bobbi, Pritt, Bobbi S , Amin, Alpesh , Bertagnolli, Monica M. , Chow, Daniel S. , Gaspar, Fraser W. , Jones, Stephen L. , O’Horo, John C. , Razonable, Raymund R. , Vahidy, Farhaan S

Mayo Clinic

JAMA Network Open | April 24, 2023 | Volume: 6 | Issue: 4 | Pages: e239694

10.1001/jamanetworkopen.2023.9694 | PMID 37093599 Get It

ImportanceEvidence on the effectiveness and safety of COVID-19 therapies across a diverse population with varied risk factors is needed to inform clinical practice.ObjectiveTo assess the safety of neutralizing monoclonal antibodies (nMAbs) for the treatment of COVID-19 and their association with adverse outcomes.Design, Setting, and ParticipantsThis retrospective cohort study included 167 183 patients from a consortium of 4 health care systems based in California, Minnesota, Texas, and Utah. The study included nonhospitalized patients 12 years and older with a positive COVID-19 laboratory test collected between November 9, 2020, and January 31, 2022, who met at least 1 emergency use authorization criterion for risk of a poor outcome.ExposureFour nMAb products (bamlanivimab, bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab) administered in the outpatient setting.Main Outcomes and MeasuresClinical and SARS-CoV-2 genomic sequence data and propensity-adjusted marginal structural models were used to assess the association between treatment with nMAbs and 4 outcomes: all-cause emergency department (ED) visits, hospitalization, death, and a composite of hospitalization or death within 14 days and 30 days of the index date (defined as the date of the first positive COVID-19 test or the date of referral). Patient index dates were categorized into 4 variant epochs: pre-Delta (November 9, 2020, to June 30, 2021), Delta (July 1 to November 30, 2021), Delta and Omicron BA.1 (December 1 to 31, 2021), and Omicron BA.1 (January 1 to 31, 2022).ResultsAmong 167 183 patients, the mean (SD) age was 47.0 (18.5) years; 95 669 patients (57.2%) were female at birth, 139 379 (83.4%) were White, and 138 900 (83.1%) were non-Hispanic. A total of 25 241 patients received treatment with nMAbs. Treatment with nMAbs was associated with lower odds of ED visits within 14 days (odds ratio [OR], 0.76; 95% CI, 0.68-0.85), hospitalization within 14 days (OR, 0.52; 95% CI, 0.45-0.59), and death within 30 days (OR, 0.14; 95% CI, 0.10-0.20). The association between nMAbs and reduced risk of hospitalization was stronger in unvaccinated patients (14-day hospitalization: OR, 0.51; 95% CI, 0.44-0.59), and the associations with hospitalization and death were stronger in immunocompromised patients (hospitalization within 14 days: OR, 0.31 [95% CI, 0.24-0.41]; death within 30 days: OR, 0.13 [95% CI, 0.06-0.27]). The strength of associations of nMAbs increased incrementally among patients with a greater probability of poor outcomes; for example, the ORs for hospitalization within 14 days were 0.58 (95% CI, 0.48-0.72) among those in the third (moderate) risk stratum and 0.41 (95% CI, 0.32-0.53) among those in the fifth (highest) risk stratum. The association of nMAb treatment with reduced risk of hospitalizations within 14 days was strongest during the Delta variant epoch (OR, 0.37; 95% CI, 0.31-0.43) but not during the Omicron BA.1 epoch (OR, 1.29; 95% CI, 0.68-2.47). These findings were corroborated in the subset of patients with viral genomic data. Treatment with nMAbs was associated with a significant mortality benefit in all variant epochs (pre-Delta: OR, 0.16 [95% CI, 0.08-0.33]; Delta: OR, 0.14 [95% CI, 0.09-0.22]; Delta and Omicron BA.1: OR, 0.10 [95% CI, 0.03-0.35]; and Omicron BA.1: OR, 0.13 [95% CI, 0.02-0.93]). Potential adverse drug events were identified in 38 treated patients (0.2%).Conclusions and RelevanceIn this study, nMAb treatment for COVID-19 was safe and associated with reductions in ED visits, hospitalization, and death, although it was not associated with reduced risk of hospitalization during the Omicron BA.1 epoch. These findings suggest that targeted risk stratification strategies may help optimize future nMAb treatment decisions.
Higher systolic blood pressure in early‐mid adulthood is associated with poorer cognitive performance in those with a dominantly inherited Alzheimer's disease mutation but not in non‐carriers. Results from the DIAN study
Xu, Ying , Aung, Htein Linn , Chhatwal, Jasmeer P. , Day, Gregory S. , Fagan, Anne M. , Farlow, Martin R. , Gordon, Brian A. , Kehoe, Patrick G. , Xiong, Chengjie , Mori, Hiroshi , Morris, John C. , Wharton, Whitney , Humburg, Peter , Peters, Ruth , (DIAN), Dominantly Inherited Alzheimer Network, Vöglein, Jonathan , Peters, Ruth , Gordon, Brian A , Day, Gregory S , Vöglein, Jonathan , Xiong, Chengjie , Morris, John C , Bateman, Randall J. , Brooks, William S. , Schofield, Peter R. , (DIAN), Dominantly Inherited Alzheimer Network

Mayo Clinic

Alzheimer's & Dementia | April 23, 2023 | Volume: 19 | Issue: 11 | Pages: 4999-5009

10.1002/alz.13082 | PMID 37087693 Get It

AbstractBACKGROUNDThe Dominantly Inherited Alzheimer Network (DIAN) is a longitudinal observational study that collects data on cognition, blood pressure (BP), and other variables from autosomal‐dominant Alzheimer's disease mutation carriers (MCs) and non‐carrier (NC) family members in early to mid‐adulthood, providing a unique opportunity to evaluate BP and cognition relationships in these populations.METHODWe examined cross‐sectional and longitudinal relationships between systolic and diastolic BP and cognition in DIAN MC and NC.RESULTSData were available from 528 participants, who had a mean age of 38 (SD = 11) and were 42% male and 61% MCs, at a median follow‐up of 2 years. Linear‐multilevel models found only cross‐sectional associations in the MC group between higher systolic BP and poorer performance on language (β = −0.181 [−0.318, −0.044]), episodic memory (−0.212 [−0.375, −0.049]), and a composite cognitive measure (−0.146 [−0.276, −0.015]). In NCs, the relationship was cross‐sectional only and present for language alone.DISCUSSIONHigher systolic BP was cross‐sectionally but not longitudinally associated with poorer cognition, particularly in MCs. BP may influence cognition gradually, but further longitudinal research is needed.